These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7664501)

  • 1. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Jolain B; Pettitt D
    Clin Ther; 1995; 17(3):572-80. PubMed ID: 7585861
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
    Ginsberg HN
    Clin Cardiol; 1995 Jun; 18(6):307-15. PubMed ID: 7664504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In process].
    Reisdorf S
    Med Monatsschr Pharm; 2017 Jun; 40(6):271-3. PubMed ID: 29979855
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design.
    Black D; Davidson M; Koren M; Bakker-Arkema R; Tresh P; McLain R; Smith D; Hunninghake D
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):278-85. PubMed ID: 10170452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing expenditures for statin-type lipid-lowering agents.
    Am J Health Syst Pharm; 1998 May; 55(10):995-6, 999. PubMed ID: 9606450
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 9. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HMG-CoA reductase inhibitors].
    Yamamoto A
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
    [No Abstract]   [Full Text] [Related]  

  • 11. Lipid-lowering drugs.
    Med Lett Drugs Ther; 2016 Oct; 58(1506):133-140. PubMed ID: 27755510
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatment.
    Shviro I; Leitersdorf E
    Cardiology; 1996; 87(6):469-75. PubMed ID: 8904672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fighting high cholesterol levels--lipid lowering drugs.
    Fidge NH
    Med J Aust; 1993 Dec 6-20; 159(11-12):815-9. PubMed ID: 8264477
    [No Abstract]   [Full Text] [Related]  

  • 14. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 15. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
    Rackley CE
    Postgrad Med; 1996 Nov; 100(5):61-5, 70-2. PubMed ID: 8917325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P
    Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Needed: pragmatic clinical trials for statin-intolerant patients.
    Maningat P; Breslow JL
    N Engl J Med; 2011 Dec; 365(24):2250-1. PubMed ID: 22085320
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipid-lowering drugs: focus on HMG-CoA reductase inhibitors. Introduction.
    Thompson GR
    Atherosclerosis; 1991 Dec; 91 Suppl():S1-2. PubMed ID: 1789811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.